Genprex, Inc. (GNPX)

NASDAQ: GNPX · IEX Real-Time Price · USD
+0.04 (2.94%)
At close: Jun 24, 2022 4:00 PM
+0.01 (0.86%)
After-hours: Jun 24, 2022 5:15 PM EDT

Company Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.

Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex, Inc.
Genprex Logo
Country United States
Founded 2009
IPO Date Mar 29, 2018
Industry Biotechnology
Sector Health Care
Employees 17
CEO J. Rodney Varner

Contact Details

1601 Trinity St Bldg B
Austin, Texas 78712-1765
United States
Phone 877 774 4679

Stock Details

Ticker Symbol GNPX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001595248

Key Executives

Name Position
John Rodney Varner Co-Founder, Chairman, President and Chief Executive Officer
Ryan M. Confer M.S. Chief Financial Officer
Catherine M. Vaczy Esq. Executive Vice President, General Counsel, Corporate Secretary and Chief Strategy Officer
Dr. Hemant Kumar C.P.M., EMBA, Ph.D. Chief Manufacturing and Technology Officer
Kalyn Dabbs Senior Manager of Communications and Marketing
David M. Schloss Senior Vice President of Human Resources
Thomas C. Gallagher Esq. Senior Vice President of Intellectual Property and Licensing
Dr. William E. Gannon Jr. Member of Clinical Advisory Board and Vice President of Regulatory Affairs
Dr. Mark S. Berger M.D. Chief Medical Officer
Greg Jancarik C.M.A., CPA, M.B.A. Corporate Controller

Latest SEC Filings

Date Type Title
May 13, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 5, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 5, 2022 8-K Current report
Apr 28, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2022 DEF 14A Other definitive proxy statements
Apr 27, 2022 8-K Current report
Apr 14, 2022 PRE 14A Other preliminary proxy statements
Mar 31, 2022 8-K Current report
Mar 30, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 2, 2022 8-K Current report